Koch Institute Symposium on Cancer Immunology and Immunotherapy

Adam Drake; Nikhil S Joshi; Gregory L Szeto; Eric Zhu; Herman N Eisen; Darrell J Irvine

doi:10.1158/2326-6066.CIR-13-0116

Koch Institute Symposium on Cancer Immunology and Immunotherapy

Cancer Immunol Res. 2013 Oct:1:217-222. doi: 10.1158/2326-6066.CIR-13-0116.

Authors

Adam Drake¹, Nikhil S Joshi¹, Gregory L Szeto¹, Eric Zhu², Herman N Eisen³, Darrell J Irvine⁴

Affiliations

¹ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
² Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
³ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
⁴ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Materials Science & Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139 ; Howard Hughes Medical Institute, Chevy Chase, MD 20815.

Abstract

The 12^th annual summer symposium of The Koch Institute for Integrative Cancer Research at MIT was held in Cambridge, MA, on June 14^th, 1023. The symposium entitled "Cancer Immunology and Immunotherapy" focused on recent advances in preclinical research in basic immunology and biomedical engineering, and their clinical application in cancer therapies. The day-long gathering also provided a forum for discussion and potential collaborations between engineers and clinical investigators. The major topics presented include: (i) enhancement of adoptive cell therapy by engineering to improve the ability and functionality of T-cells against tumor cells; (ii) current therapies using protein and antibody therapeutics to modulate endogenous anti-tumor immunity; and (iii) new technologies to identify molecular targets and assess therapeutic efficacy, and devices to control and target drug delivery more effectively and efficiently.

Abstract

Grants and funding